Edition:
India

Dermira Inc (DERM.OQ)

DERM.OQ on NASDAQ Stock Exchange Global Select Market

28.21USD
19 Jan 2018
Change (% chg)

$0.23 (+0.82%)
Prev Close
$27.98
Open
$27.93
Day's High
$28.36
Day's Low
$27.75
Volume
140,215
Avg. Vol
145,320
52-wk High
$38.75
52-wk Low
$21.39

Chart for

About

Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and... (more)

Overall

Beta: --
Market Cap(Mil.): $1,130.87
Shares Outstanding(Mil.): 41.59
Dividend: --
Yield (%): --

Financials

BRIEF-Dermira posts Q3 loss $4.30/shr, says FDA accepts NDA for glycopyrronium tosylate

* Dermira reports third quarter 2017 financial results and announces that FDA accepts new drug application for glycopyrronium tosylate for the treatment of patients with primary axillary hyperhidrosis

07 Nov 2017

BRIEF-Dermira and UCB agree to end collaboration agreement for Cimzia

* Dermira and UCB agree to end collaboration agreement for Cimzia

07 Nov 2017

BRIEF-Dermira highlights new long-term safety data for glycopyrronium tosylate

* Dermira highlights new long-term safety data for glycopyrronium tosylate in primary axillary hyperhidrosis at fall clinical dermatology conference

13 Oct 2017

BRIEF-Dermira completes patient enrollment in two phase 3 trials of olumacostat glasaretil for the treatment of acne vulgaris

* Dermira completes patient enrollment in two phase 3 pivotal trials of olumacostat glasaretil for the treatment of acne vulgaris

05 Oct 2017

BRIEF-Dermira presents new data showing impact of primary axillary hyperhidrosis on patients

* Dermira -‍ presented new patient-reported outcomes data from two Phase 3 clinical trials showing impact of primary axillary hyperhidrosis on patients​

13 Sep 2017

BRIEF-Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab

* Dermira enters into agreement to license exclusive, worldwide rights to Lebrikizumab

08 Aug 2017

BRIEF-UCB and Dermira announce US and EU regulatory submissions for Cimzia

* UCB AND DERMIRA ANNOUNCE U.S. AND EU REGULATORY SUBMISSIONS FOR CIMZIA (CERTOLIZUMAB PEGOL) FOR THE TREATMENT OF MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS Source text: http://bit.ly/2ty2bhV Further company coverage: (Gdynia Newsroom)

25 Jul 2017

Competitors

Earnings vs. Estimates